Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refin

Verastem (VSTM) was a big mover last session on higher-than-average trading volume. The latest trend

RBC Capital analyst Leonid Timashev maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Verastem (NASDAQ:VSTM) with a Buy

Verastem, Inc. (VSTM) Discusses Preliminary TARGET-D 101 Data for VS-7375 in KRAS G12D Mutated Cance

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines fo

BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--VS-7375 (investigational KRAS G12D ON/OFF inhibitor) demonst

Verastem, Inc. is maintained at a Buy rating, driven by upcoming clinical catalysts and positive ear

Verastem, Inc. (NASDAQ:VSTM) stock is trading higher on Wednesday as the company announced positive

BOSTON--(BUSINESS WIRE)---- $VSTM #CancerResearch--Verastem Oncology announces updated results from

BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--Verastem doses first patient in TARGET-D 201, a registration

BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--Verastem Oncology to report progress across the VS-7375 oral

BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--FDA grants Fast Track designation to VS-7375, an oral invest

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines f

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to

Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-

The heavy selling pressure might have exhausted for Verastem (VSTM) as it is technically in oversold

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to

Verastem NASDAQ: VSTM reported first-quarter 2026 net product revenue of $18.7 million for AVMAPKI F

BOSTON--(BUSINESS WIRE)--Today, STAAR Low-Grade Serous Ovarian Cancer Foundation, Not These Ovaries,

Verastem, Inc. (VSTM) Q1 2026 Earnings Call Transcript

Verastem (VSTM) came out with a quarterly loss of $0.46 per share in line with the Zacks Consensus E

  On Friday morning, 446 companies hit new 52-week lows.

  During Wednesday's trading, 517 companies set new 52-week lows.

  On Tuesday, 838 companies hit new 52-week lows.

  On Thursday, 930 stocks hit new 52-week lows.

    Before 10 a.m. ET on Wednesday, 105 companies hit new 52-week highs.